Patent · US Active

Fused imidazoles as mIDH1 inhibitors

US10919862B2 · kind B2 · utility

0Cited by

10References

25Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Olaf Panknin · Berlin, DE
Ingo Hartung · Berlin, DE
Hartmut Rehwinkel · Berlin, DE
Duy Nguyen · Berlin, DE
Ludwig Zorn · Berlin, DE
Petra HELFRICH · Falkensee, DE
Katja Zimmermann · Mülheim an der Ruhr, DE
Roland Neuhaus · Berlin, DE

Key dates

Filing date	Jul 14, 2016
Grant date	Feb 16, 2021
Priority date	—
Expiry date	Jul 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12P17/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.